Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Einstein

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
European Urology Focus|February 27, 2026
ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapyAndrew L Laccetti, Matthew R Smith, Howard I Scher, et al.
Surgery|October 31, 2002
Portal vein thrombi after restorative proctocolectomyFeza H Remzi, Victor W Fazio, Mustafa Oncel, et al.
AJR. American Journal of Roentgenology|June 27, 2012
Contrast-to-noise ratio and low-contrast object resolution on full- and low-dose MDCT: SAFIRE versus filtered back projection in a low-contrast object phantom and in the liverMark E Baker, Frank Dong, Andrew Primak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate CancerZachary Quinn, Benjamin Leiby, Guru Sonpavde, et al.
Radiology|April 15, 2016
Diagnostic Accuracy of CT Enterography for Active Inflammatory Terminal Ileal Crohn Disease: Comparison of Full-Dose and Half-Dose Images Reconstructed with FBP and Half-Dose Images with SAFIRENamita S Gandhi, Mark E Baker, Ajit H Goenka, et al.
Journal for Immunotherapy of Cancer|April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Biorxiv : the Preprint Server for Biology|August 8, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusionFen Ma, Sen Chen, Luigi Cecchi, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Nature Communications|July 2, 2025
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancerKei Mizuno, Sheng-Yu Ku, Varadha Balaji Venkadakrishnan, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
European Urology Focus|February 27, 2026
ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapyAndrew L Laccetti, Matthew R Smith, Howard I Scher, et al.
Surgery|October 31, 2002
Portal vein thrombi after restorative proctocolectomyFeza H Remzi, Victor W Fazio, Mustafa Oncel, et al.
AJR. American Journal of Roentgenology|June 27, 2012
Contrast-to-noise ratio and low-contrast object resolution on full- and low-dose MDCT: SAFIRE versus filtered back projection in a low-contrast object phantom and in the liverMark E Baker, Frank Dong, Andrew Primak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate CancerZachary Quinn, Benjamin Leiby, Guru Sonpavde, et al.
Radiology|April 15, 2016
Diagnostic Accuracy of CT Enterography for Active Inflammatory Terminal Ileal Crohn Disease: Comparison of Full-Dose and Half-Dose Images Reconstructed with FBP and Half-Dose Images with SAFIRENamita S Gandhi, Mark E Baker, Ajit H Goenka, et al.
Journal for Immunotherapy of Cancer|April 11, 2024
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Biorxiv : the Preprint Server for Biology|August 8, 2025
Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusionFen Ma, Sen Chen, Luigi Cecchi, et al.
Journal for Immunotherapy of Cancer|March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Nature Communications|July 2, 2025
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancerKei Mizuno, Sheng-Yu Ku, Varadha Balaji Venkadakrishnan, et al.
Pageof 2